Cobb Stuart
Chief Scientific Officer
Cobb Stuart has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 17, 2026.
On the most recent filing, Cobb Stuart is listed as Chief Scientific Officer at Neurogene Inc. Inside the rolling window, Cobb Stuart reported no open-market purchases and 1 open-market sale totaling $141K in NGNE.
Companies traded
Other insiders at NGNE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$141K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Cobb Stuart made?
Cobb Stuart has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Cobb Stuart trade?
Cobb Stuart has filed SEC Form 4 disclosures for 1 company, including NGNE.
When was Cobb Stuart's most recent SEC Form 4 filing?
Cobb Stuart's most recent SEC Form 4 filing on Tracefour is dated Mar 17, 2026.
What is Cobb Stuart's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Cobb Stuart is listed as Chief Scientific Officer.
What is Cobb Stuart's total buy and sell value in the current window?
Inside the rolling retention window, Cobb Stuart bought $0 and sold $141K based on SEC Form 4 filings.
What was Cobb Stuart's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,797 NGNE shares on 2026-03-13, worth $141K, per SEC Form 4 filings.